S.C. Ropharma Statistics

Total Valuation

S.C. Ropharma has a market cap or net worth of RON 79.25 million. The enterprise value is 227.63 million.

Market Cap	79.25M
Enterprise Value	227.63M

Important Dates

The next estimated earnings date is Friday, April 25, 2025.

Earnings Date	Apr 25, 2025
Ex-Dividend Date	n/a

Share Statistics

S.C. Ropharma has 511.27 million shares outstanding. The number of shares has increased by 0.90% in one year.

Current Share Class	n/a
Shares Outstanding	511.27M
Shares Change (YoY)	+0.90%
Shares Change (QoQ)	+1.79%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	n/a

Valuation Ratios

The trailing PE ratio is 2,259.02.

PE Ratio	2,259.02
Forward PE	n/a
PS Ratio	0.07
PB Ratio	0.33
P/TBV Ratio	0.44
P/FCF Ratio	3.05
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 5.34, with an EV/FCF ratio of 8.77.

EV / Earnings	6,488.80
EV / Sales	0.19
EV / EBITDA	5.34
EV / EBIT	10.80
EV / FCF	8.77

Financial Position

The company has a current ratio of 1.01, with a Debt / Equity ratio of 0.66.

Current Ratio	1.01
Quick Ratio	0.60
Debt / Equity	0.66
Debt / EBITDA	3.89
Debt / FCF	6.40
Interest Coverage	3.54

Financial Efficiency

Return on equity (ROE) is 2.00% and return on invested capital (ROIC) is 3.29%.

Return on Equity (ROE)	2.00%
Return on Assets (ROA)	1.60%
Return on Capital (ROIC)	3.29%
Revenue Per Employee	986,598
Profits Per Employee	29
Employee Count	894
Asset Turnover	1.44
Inventory Turnover	5.00

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -21.43% in the last 52 weeks. The beta is 0.23, so S.C. Ropharma's price volatility has been lower than the market average.

Beta (5Y)	0.23
52-Week Price Change	-21.43%
50-Day Moving Average	0.17
200-Day Moving Average	0.18
Relative Strength Index (RSI)	42.03
Average Volume (20 Days)	90,130

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, S.C. Ropharma had revenue of RON 1.19 billion and earned 35,080 in profits. Earnings per share was 0.00.

Revenue	1.19B
Gross Profit	270.69M
Operating Income	21.09M
Pretax Income	14.83M
Net Income	35,080
EBITDA	31.70M
EBIT	21.09M
Earnings Per Share (EPS)	0.00

Full Income Statement

Balance Sheet

The company has 32.48 million in cash and 166.03 million in debt, giving a net cash position of -133.56 million or -0.26 per share.

Cash & Cash Equivalents	32.48M
Total Debt	166.03M
Net Cash	-133.56M
Net Cash Per Share	-0.26
Equity (Book Value)	252.99M
Book Value Per Share	0.47
Working Capital	6.37M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 45.02 million and capital expenditures -19.07 million, giving a free cash flow of 25.96 million.

Operating Cash Flow	45.02M
Capital Expenditures	-19.07M
Free Cash Flow	25.96M
FCF Per Share	0.05

Full Cash Flow Statement

Margins

Gross margin is 22.81%, with operating and profit margins of 1.78% and 0.00%.

Gross Margin	22.81%
Operating Margin	1.78%
Pretax Margin	1.25%
Profit Margin	0.00%
EBITDA Margin	2.67%
EBIT Margin	1.78%
FCF Margin	2.19%

Dividends & Yields

S.C. Ropharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.90%
Shareholder Yield	-0.90%
Earnings Yield	0.04%
FCF Yield	32.75%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

S.C. Ropharma has an Altman Z-Score of 1.57. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.57
Piotroski F-Score	n/a